What were the main drivers of revenue growth in the third quarter of 2004?

The filing indicates that revenue growth was primarily driven by the performance of key pharmaceutical products. While specific product names are not detailed in this summary, investors should refer to the 'Management's Discussion and Analysis' section of the full 10-Q for a breakdown of product-specific contributions to revenue.

What significant legal proceedings is Eli Lilly involved in, and what is their potential impact?

Item 1 of Part II, 'Legal Proceedings,' would contain details on any significant legal matters. These could range from patent disputes to regulatory actions. Investors should review this section carefully for any potential financial liabilities or operational disruptions that could affect the company.

How is the company managing the impact of patent expirations on its product portfolio?

The 'Management's Discussion and Analysis' section is the primary area to understand the company's strategy for dealing with patent expirations. This typically involves discussions on the launch of new products, lifecycle management of existing drugs, and efforts to mitigate the revenue impact from generic competition.

What is the overall financial health of the company as indicated by the condensed financial statements?

The Consolidated Condensed Statements of Income, Balance Sheets, and Cash Flows provide a snapshot of the company's financial health. Investors should analyze trends in revenue, profitability, debt levels, and cash flow generation to assess the company's financial stability and operational performance.

LLY 10-Q Quarterly Report Q3 FY2004 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company (LLY) reported its third-quarter 2004 financial results, showcasing continued revenue growth driven by key pharmaceutical products. While the company navigated a complex operating environment, including patent expirations and ongoing litigation, the underlying business demonstrated resilience. Investors should note the company's strategic focus on pipeline development and its efforts to manage the impact of competition, which are crucial for future performance and long-term value creation.

Key Highlights

1Reported revenue growth for the third quarter of 2004.
2Discussed the impact of key pharmaceutical products on overall sales performance.
3Addressed ongoing legal proceedings that could have financial implications.
4Provided an update on the company's financial condition and results of operations.
5Detailed the company's control and procedures in place.
6Included information on unregistered sales of equity securities and use of proceeds.

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 2004

Summary

Key Highlights

Frequently Asked Questions